The FDA has approved the third of a new type of drug to prevent migraine headaches in adults. Galcanezumab-gnlm targets calcitonin gene-related peptide (CGRP), a molecule that's produced in nerve cells of the brain and spinal cord. The FDA approved two other CGRP drugs for migraine -- erenumab and fremanezumab-vfrm -- earlier this year. In a news release, drugmaker Eli Lilly and Co.
says the injectable drug will be available to patients "shortly after approval." How Does Migraine Affect Your Body? Galcanezumab-gnlm targets calcitonin gene-related peptide (CGRP), a molecule that's produced in nerve cells of the brain and spinal cord. The FDA approved two other CGRP drugs for migraine -- erenumab and fremanezumab-vfrm -- earlier this year. In a news release, drugmaker says the injectable drug will be available to patients "shortly after approval." "I have lived with migraine for more than…
